Impact of Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, on Psoriasis in Patients with Active Psoriatic Arthritis: Results from a Phase 2 Trial. J of Skin [Internet]. 2024 Mar. 18 [cited 2025 Apr. 19];8(2):s383. Available from: https://skin.dermsquared.com/skin/article/view/2678